Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 1
1998 3
1999 2
2000 2
2002 2
2003 3
2004 1
2005 4
2006 9
2007 5
2008 6
2009 6
2010 5
2011 7
2012 6
2013 6
2014 9
2015 5
2016 4
2017 5
2018 4
2019 5
2020 1
2021 2
2022 6
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 21680689

95 results

Results by year

Filters applied: . Clear all
Page 1
SEP-225289 serotonin and dopamine transporter occupancy: a PET study.
DeLorenzo C, Lichenstein S, Schaefer K, Dunn J, Marshall R, Organisak L, Kharidia J, Robertson B, Mann JJ, Parsey RV. DeLorenzo C, et al. J Nucl Med. 2011 Jul;52(7):1150-5. doi: 10.2967/jnumed.110.084525. Epub 2011 Jun 16. J Nucl Med. 2011. PMID: 21680689 Free PMC article. Clinical Trial.
Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography.
Comley RA, Salinas CA, Slifstein M, Petrone M, Marzano C, Bennacef I, Shotbolt P, Van der Aart J, Neve M, Iavarone L, Gomeni R, Laruelle M, Gray FA, Gunn RN, Rabiner EA. Comley RA, et al. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7. doi: 10.1124/jpet.112.202895. Epub 2013 May 17. J Pharmacol Exp Ther. 2013. PMID: 23685546 Clinical Trial.
Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836.
Zheng M, Appel L, Luo F, Lane R, Burt D, Risinger R, Antoni G, Cahir M, Keswani S, Hayes W, Bhagwagar Z. Zheng M, et al. Psychopharmacology (Berl). 2015 Feb;232(3):529-40. doi: 10.1007/s00213-014-3688-x. Epub 2014 Aug 14. Psychopharmacology (Berl). 2015. PMID: 25116481 Clinical Trial.
Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor.
Smith JA, Bourdet DL, Daniels OT, Ding YS, Gallezot JD, Henry S, Kim KH, Kshirsagar S, Martin WJ, Obedencio GP, Stangeland E, Tsuruda PR, Williams W, Carson RE, Patil ST. Smith JA, et al. Int J Neuropsychopharmacol. 2014 Dec 13;18(2):pyu027. doi: 10.1093/ijnp/pyu027. Int J Neuropsychopharmacol. 2014. PMID: 25522383 Free PMC article.
Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane.
Spencer TJ, Bonab AA, Dougherty DD, Mirto T, Martin J, Clarke A, Fischman AJ. Spencer TJ, et al. J Clin Psychiatry. 2012 Mar;73(3):346-52. doi: 10.4088/JCP.10m06393. Epub 2011 Nov 1. J Clin Psychiatry. 2012. PMID: 22154896 Clinical Trial.
95 results